Eye drops with a caspase-9 inhibitor prevent retinal injury from retinal vein occlusion. In the left image, RVO causes swelling in the retina and the retinal layers are less distinct. In the right image, the eye drops have restored the distinct layers of the retina. (Troy lab)
Researchers at Columbia University Irving Medical Center have developed eye drops that could prevent vision loss after retinal vein occlusion, a major cause of blindness for millions of adults worldwide.
A study, in mice, suggests that the experimental therapy—which targets a common cause of neurodegeneration and vascular leakage in the eye—could have broader therapeutic effects than existing drugs.
The study was published in Nature Communications.
What is Retinal Vein Occlusion?
Retinal vein occlusion occurs when a major vein that drains blood from the retina is blocked, usually due to a blood clot. As a result, blood and other fluids leak into the retina, damaging specialized light-sensing neurons called photoreceptors.
Standard treatment for the condition currently relies on drugs that reduce fluid leakage from blood vessels and abnormal blood vessel growth. But there are significant drawbacks. These therapies require repeated injections directly into the eye, and for the patients who brave this daunting prospect, the treatment ultimately fails to prevent vision loss in the majority of cases.
The new treatment targets an enzyme called caspase-9, says Carol M. Troy, MD, PhD, professor of pathology & cell biology and of neurology in the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain at Columbia University Vagelos College of Physicians and Surgeons, who led the studies. Under normal conditions, caspase-9 is believed to be primarily involved in programmed cell death, a tightly regulated mechanism for naturally eliminating damaged or excess cells.
In studies of mice, the Troy lab discovered that when blood vessels are injured by retinal vein occlusion, caspase-9 becomes uncontrollably activated, triggering processes that can damage the retina.
Eye Drops Prevent Retinal Injury
The Troy lab found that a highly selective caspase-9 inhibitor, delivered in the form of eye drops, improved a variety of clinical measures of retinal function in a mouse model of the condition. Most importantly, the treatment reduced swelling, improved blood flow, and decreased neuronal damage in the retina.
“We believe these eye drops may offer several advantages over existing therapies,” says Troy. “Patients could administer the drug themselves and wouldn’t have to get a series of injections. Also, our eye drops target a different pathway of retinal injury and thus may help patients who do not respond to the current therapy.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Retinal vein occlusion
- As Faricimab moves closer to clinical approval for additional indication, what is the likelihood that the drug will be approved?
Faricimab is under clinical development by F. Hoffmann-La Roche and is currently in the Phase III and Pre-Registration in clinical pathway.
- Brown on Ophthalmology
What is the impact on retinal vein occlusion treatment? Experts And Viewpoints, May 25, 2010 Anti-VEGF Therapy and Laser: Changing the Game in Diabetic Macular Edema Treatment New studies show ...
- Retinal Vein Occlusions: Could Recent Developments Be Practice-Changing?
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
- Central Retinal Vein Occlusion (CRVO)
Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back of the eye. Occurring mostly in ...
- Occlusion Devices Market is expected to generate a revenue of USD 3.7 Billion by 2028, Globally, at 5.09% CAGR: Verified Market Research®
And Forecast Retinal Vein Occlusion Market By Type (Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion), By Condition (Ischemic, Non-Ischemic), By Therapy (Laser, Anti-VEGF ...
Go deeper with Google Headlines on:
Retinal vein occlusion
[google_news title=”” keyword=”retinal vein occlusion” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Vascular dysfunction
- World renowned expert to speak on heart disease and how far we have come
POCATELLO — Portneuf Heart and Vascular Institute has invited Eric E. Roselli, M.D., of adult cardiac surgery and surgical director of the Aorta Center at Cleveland Clinic to present on ...
- AVS Rakes in $20M to Advance Plaque-shattering Arterial Disease Treatment
Boston-based medical device company AVS recently raised $20 million in Series B funding to bring its arterial disease treatment closer to FDA clearance. The system that AVS is developing uses pressure ...
- Vascular risk factors raise odds of Alzheimer’s disease in Blacks, Hispanics: study
Vascular risk helps to explain the outsized odds of Alzheimer’s faced by African Americans and Hispanics in the United States, a new study has found.
- Cardiovascular Systems, Inc. Announces FDA 510(k) Submission of Innova Vascular, Inc.’s Thrombectomy System
Cardiovascular Systems, Inc. (CSI ®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary ...
- Vascular Access Catheter Market (New Report) Revenue Growth is Making Marketplace Explosive During 2023-2029 | 111 Pages Report
Jan 04, 2023 (The Expresswire) -- "Pre and Post Covid Report Is Covered in Vascular Access Catheter Market | Final Report Will Add the Analysis of the ...
Go deeper with Google Headlines on:
Vascular dysfunction
[google_news title=”” keyword=”vascular dysfunction” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
